$0.857
+0.007 (+0.78%)At close
ONCY Comparative Benchmarking
In the context of the broader market, ONCY competes directly with industry leaders such as SEER and COYA. With a market capitalization of $108.38M, it holds a significant position in the sector. When comparing efficiency, ONCY's gross margin of N/A stands against SEER's 98.71% and COYA's 100.00%. Such benchmarking helps identify whether Oncolytics Biotech Inc is trading at a premium or discount relative to its financial performance.
Oncolytics Biotech Inc Financial Performance
Oncolytics has been experiencing substantial losses, with a net income of -12,679,060.40 CAD in Q1 2026 and a forward P/E of 45.45, indicating high expectations for future earnings despite current losses.
Financials
FY2026Q2
YoY:
+101.67%
-12.99M
Operating Profit
FY2026Q2
YoY:
+78.94%
-13.07M
Net Income after Tax
FY2026Q2
YoY:
+37.50%
-0.11
EPS - Diluted
FY2026Q2
YoY:
+98.22%
-11.27M
Free Cash Flow
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。